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Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via
the mTOR/4E-BP1 signaling pathway
Abstract
Methylglyoxal (MG) accumulation has been observed in human cerebrospinal fluid and body tissues under
hyperglycaemic conditions. Recent research has demonstrated that MG-induces neuronal cell apoptosis,
which promotes the development of diabetic encephalopathy. Our previous animal study has shown that
luteolin, a natural flavonoid, attenuates diabetes-associated cognitive dysfunction. To further explore the
neuroprotective properties of luteolin, we investigated the inhibitive effect of luteolin on MG-induced
apoptosis in PC12 neuronal cells. We found that MG inhibited cell viability in a dose-dependent manner and
induced apoptosis in PC12 cells. Pretreatment with Luteolin significantly elevated cell viability, reduced MG-
induced apoptosis, inhibited the activation of the mTOR/4E-BP1 signaling pathway, and decreased pro-
apoptotic proteins, Bax, Cytochrome C as well as caspase-3. Furthermore, we found that pretreatment with
the mTOR inhibitor, rapamycin, significantly reduced the expression of the pro-apoptotic protein Bax.
Therefore, these observations unambiguously suggest that the inhibitive effect of Luteolin against MG-
induced apoptosis in PC12 cells is associated with inhibition of the mTOR/4E-BP1 signaling pathway.
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Luteolin, a natural flavonoid, 
inhibits methylglyoxal induced 
apoptosis via the mTOR/4E-BP1 
signaling pathway
Yi Liu1, Jie Huang1, Xian Zheng1, Xia Yang1, Yan Ding1, Tongyong Fang1, Yuyun Zhang1, 
Shuaishuai Wang1, Xiaofei Zhang1, Xuan Luo1, Anlei Guo1, Kelly A. Newell3, Yinghua Yu2,3 & 
Xu-Feng Huang  2,3
Methylglyoxal (MG) accumulation has been observed in human cerebrospinal fluid and body tissues 
under hyperglycaemic conditions. Recent research has demonstrated that MG-induces neuronal cell 
apoptosis, which promotes the development of diabetic encephalopathy. Our previous animal study 
has shown that luteolin, a natural flavonoid, attenuates diabetes-associated cognitive dysfunction. 
To further explore the neuroprotective properties of luteolin, we investigated the inhibitive effect of 
luteolin on MG-induced apoptosis in PC12 neuronal cells. We found that MG inhibited cell viability in a 
dose-dependent manner and induced apoptosis in PC12 cells. Pretreatment with Luteolin significantly 
elevated cell viability, reduced MG-induced apoptosis, inhibited the activation of the mTOR/4E-BP1 
signaling pathway, and decreased pro-apoptotic proteins, Bax, Cytochrome C as well as caspase-3. 
Furthermore, we found that pretreatment with the mTOR inhibitor, rapamycin, significantly reduced 
the expression of the pro-apoptotic protein Bax. Therefore, these observations unambiguously suggest 
that the inhibitive effect of Luteolin against MG-induced apoptosis in PC12 cells is associated with 
inhibition of the mTOR/4E-BP1 signaling pathway.
Patients with long-standing diabetes commonly develop diabetic encephalopathy, which is characterized by cog-
nitive decline1, neuronal apoptosis2, 3, as well as neurochemical and structural abnormalities in the cortex and 
hippocampus4, 5. Although the pathogenesis of diabetic encephalopathy is complex and not fully understood, 
methylglyoxal (MG) accumulation has been considered as one of the major contributing causes6, 7. MG is a reac-
tive dicarbonyl compound physiologically produced from glycolytic pathway intermediates8, 9. The MG concen-
tration is significantly increased in the plasma and hippocampal tissue of the brain in patients with diabetes and 
is closely related to the development of diabetic complications7, 10. MG is able to induce cellular damage, neuronal 
apoptosis and activation of apoptosis related proteins in the brain11–13, which play an important role in the patho-
genesis of many neurodegenerative disorders14.
Mitochondrial apoptosis pathways play a major role in neuronal apoptosis in diabetes. They integrate death 
signals through Bcl-2/Bax family members and coordinate caspase activation through the release of Cytochrome 
C (Cyt C). Bcl-2 regulates the translocation of the pro-apoptotic protein, Bax, from the cytosol to the outer mito-
chondrial membrane15. Bax increases membrane permeability and promotes the release of Cyt C, which binds 
with procaspase-9, resulting in its cleavage to form activated caspase-916, 17. The activated caspase-9, in turn, 
cleaves procaspase-3 to its active form, which induces cell apoptosis18. In the hippocampus of streptozotocin 
(STZ)-induced diabetic rats, Bax and caspase-3 mRNA or protein levels are considerably increased and related to 
impaired cognition as measured by the Morris water maze3. Therefore, neuronal apoptosis is likely to account for 
the concomitant emergence of cognitive impairments in the diabetic status.
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Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase, which is activated by PI3K/
AKT and involved in the regulation of cellular apoptosis19–21. It regulates both protein synthesis and degradation, 
longevity and cytoskeletal formation22, 23. mTOR activates its downstream effector, eukaryotic initiation factor 
4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase (S6K, also named p70S6K)24, 25, which subse-
quently leads to translation of pro-apoptotic proteins26, 27. Through this pathway, mTOR also phosphorylates and 
inactivates the anti-apoptotic protein Bcl-228. The mTOR signaling pathway is hyperactive in the hippocampus 
of STZ-induced diabetic mice, while inhibiting mTOR signaling has been shown to prevent the cognitive defi-
cits associated with this model29. Collectively, these studies provide potential mechanistic insight for the role of 
mTOR/4E-BP1 in neuronal apoptosis.
Luteolin is a natural flavonoid that exists in celery, green pepper leaf and seed, chamomile tea, lonicera and 
medicinal herbs30. Previously, luteolin has shown strong anti-apoptotic31, 32, anti-oxidant33 and anti-inflammatory 
activities34. Luteolin has been found to possess neuroprotective properties in vivo and in vitro35–37. In our previous 
animal study we found that luteolin prevented cognitive decline and neuropathological alterations in the cortex 
and hippocampus of STZ-induced diabetic rats38. However, little information is available on the protective effects 
of luteolin against diabetes-associated neuronal apoptosis. In the present study, we further examined the neu-
roprotective action of luteolin. Using PC12 cell cultures, which are an established model for the investigation of 
nervous system disease39–41, we examined the role of pro-apoptotic proteins (Bax, Cyt C and caspase-3) and their 
related signaling molecules mTOR/4E-BP1 in the prevention of MG-induced neuronal apoptosis, which mimics 
the diabetics state.
Results
Luteolin dose dependently prevents MG-induced decreases in cell viability. The cytotoxicity of 
MG was examined by the MTT assay. PC12 cells were treated with various concentrations of MG (0.1, 0.25, 0.5, 
1 and 2 mM) and cell viability was examined at 12 h, 24 h and 36 h after MG exposure. Cell viability decreased 
with increasing concentrations of MG and incubation time (Fig. 1A). MG significantly reduced cell viability after 
12 hours of incubation (0.5, 1 and 2 mM), 24 hours of incubation (0.25–2 mM) and 36 hours of incubation (all 
concentrations) (all p < 0.05). Phase-contrast microscopy revealed a significant reduction in the number of cells, 
a loss of cellular neurites, shrinkage or swelling of cell bodies and disruption of the dendritic networks in PC12 
cells exposed to MG (all concentrations) for 36 hours, compared to the control group (Fig. 1B). Collectively, these 
findings suggest that exposure of PC12 neuronal cells to MG induces cytotoxicity and decreases cell viability.
To determine the effect of luteolin on MG-induced cytotoxicity, PC12 cells were pretreated with 1, 5 and 
10 μM of luteolin for 3 h, followed by 0.5 mM MG for 36 h. Luteolin dose-dependently prevented MG-induced 
reductions in cell viability, as examined by MTT (Fig. 1D). Phase-contrast microscopy images further confirmed 
the protective effect of luteolin on MG-induced cytotoxicity in PC12 cells (Fig. 1E).
Luteolin inhibits MG-induced apoptosis. Using Annexin V-FITC/PI staining and flow cytometry, we 
examined whether MG-induced growth inhibition was a result of apoptosis. As shown in Fig. 2A, treatments with 
0.1–2 mM MG resulted in an increase of apoptotic cells (both Annexin V-FITC-/PI- and Annexin V-FITC-/PI+). 
MG, dose dependently, increased rates of apoptosis in PC12 cells, with apoptosis rates of the MG groups (0.25, 
0.5, 1, 2 mM) being significantly higher than that of the Control group (Fig. 2B, p < 0.05).
Hoechst 33258 staining (Fig. 2C) also revealed that PC12 cells in the MG groups acquired typical features of 
apoptosis, including cell shrinkage, nuclear pyknosis and apoptotic bodies (Fig. 2C). Luteolin (5 and 10 μM) alle-
viated MG (0.5 mM) induced morphological changes of apoptosis in PC12 neuronal cells (Fig. 2D).
Luteolin inhibits the MG-induced activation of mTOR-4E-BP1. mTOR has a role in neurodegen-
erative diseases. Here we found that the mTOR inhibitor, rapamycin (Rap), inhibited PC12 cell viability at high 
(10 μM) but not low (0.1 and 1 μM) concentrations (see Supplementary Fig. S1A). Furthermore, Rap prevented 
the MG-induced reduction in cell viability using an MTT assay (see Supplementary Fig. S1B). Pretreatment of 
PC12 cells with 0.1 or 1 μM Rap significantly enhanced cell viability compared with the MG-treatment group, 
returning cell viability to 60% of control levels (p < 0.05). Apoptosis was subsequently measured by TUNEL 
(red) and DAPI (blue) staining after Rap at 1 μM and MG (0.5 mM) incubation (see Supplementary Fig. S1C). 
The number of TUNEL-positive cells in the MG treated group significantly increased compared with the control 
group (p < 0.05), while the number of TUNEL-positive cells was markedly reduced in the Rap (1 μM) + MG 
(0.5 mM) treated group compared with MG treated group (p < 0.05) (see Supplementary Fig. S1D). Therefore, the 
inhibition of mTOR by Rap could alleviate MG induced PC12 cell apoptosis, suggesting MG-induced reductions 
in cell viability and apoptosis could occur, at least in part, via mTOR.
To further determine whether the ability of luteolin to prevent MG-induced apoptosis is via inhibition of 
mTOR and its downstream effector 4E-BP1, we measured p-mTOR and p-4E-BP1 levels by western blot and 
immunofluorescence staining. As shown in Fig. 3A, the phosphorylation of mTOR was significantly increased 
in the MG treated group compared with the control group (p < 0.05), while luteolin (5 and 10 μM) decreased 
the phosphorylation of mTOR compared with MG treated group (p < 0.05), returning p-mTOR to control lev-
els. Luteolin (5 and 10 μM) also prevented the MG-induced increase in p-4E-BPI (Fig. 3B). To further confirm 
the results, we determined the levels of mTOR and 4E-BP1 by immunofluorescence staining. As shown in Fig.  
3C and D, the fluorescence intensity of p-mTOR and p-4E-BP1 significantly increased in the MG group, while the 
intensity of these two were significantly lower in the luteolin 10 μM + MG group compared with MG group. These 
observations suggest that luteolin potentially inhibits mTOR and may have a similar effect to Rap in PC12 cells.
Furthermore, p-AKT (mTOR upstream molecule) and p-p70S6K (p-4E-BP1 downstream molecule) were 
examined by Western blot. The phosphorylation of AKT was significantly increased in the MG group compared 
with Control group (p < 0.05), while luteolin pre-treatment (5 and 10 μM) decreased the p-AKT compared with 
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Figure 1. Luteolin (Lut) prevented MG-induced decrease in cell viability in a dose-dependent manner. (A) 
MTT assays were performed to detect viability of PC12 cells treated with MG (0.1–2.0 mM) for 12 h, 24 h 
and 36 h. Results are expressed relative to control and are presented as means ± SD of three independent 
experiments, each performed in triplicate. *p < 0.05, **p < 0.01 vs control group. (B) Representative photographs 
of cell morphology of PC12 cells treated with MG (0.1–2.0 mM) for 36 h. Morphological changes of PC12 cells 
were observed by phase-contrasted microscopy. (C) Chemical structure of Lut. (D) Morphological changes of 
PC12 cells, pretreated with Lut for 3 h, followed by MG (0.5 mM) for 36 h. Data are presented as means ± SD of 
three independent experiments, each performed in triplicate. #p < 0.01 vs control group; *p < 0.05 and **p < 0.01 
vs MG group. (E) Representative images of Lut-induced protection against MG-induced cytotoxicity. Cells were 
observed by phase-contrast microscopy.
www.nature.com/scientificreports/
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Figure 2. Luteolin (Lut) inhibited MG-induced cell apoptosis. Apoptosis assessment of PC12 cells treated with 
MG (0.1–2.0 mM) for 36 h. Lut protected PC12 cells against MG-induced apoptosis. (A) Cells were stained by 
fluorescent annexin V and propidium iodide (PI) and then examined for apoptosis by flow cytometry. (B) The 
percent of Annexin V positive cells following increasing concentrations of MG. Data are representatives from 
three independent experiments and the percentages of different populations were labeled in the figures. *p < 0.05 
and **p < 0.01 vs control group. (C) Nuclear fragmentation was assessed by nuclei staining with Hoechst 33358. 
MG (0.1–2 mM) increased the apoptosis in PC12 cells. (D) Cells were pretreated with Lut (1, 5, 10 μM) for 3 h, 
followed by 0.5 mM MG exposure for 36 h. Morphological apoptosis was determined by Hoechst 33258 staining.
www.nature.com/scientificreports/
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Figure 3. Luteolin (Lut) inhibited the activation of mTOR-4E-BP1 induced by MG. PC12 cells were treated 
with the Lut (1, 5 and 10 μM) for 3 h, followed by incubating with 0.5 mM MG for 24 h. The activation of mTOR 
(A and C) and 4E-BP1 (B and D) was determined by western blot and immunofluorecence staining. Data are 
presented as means ± SD of three independent experiments, each performed in triplicate. #p < 0.01 vs control 
group; *p < 0.05 and **p < 0.01 vs MG group. The full-length blots/gels are presented in Supplementary Figs S4 
and S5.
www.nature.com/scientificreports/
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MG group (p < 0.05) (see Supplementary Fig. S3A). Luteolin (5 and 10 μM) also prevented the MG-induced 
p-p70S6K (see Supplementary Fig. S3B).
Luteolin inhibits MG-induced expression of the apoptosis related proteins, Bax, Cyt C and 
caspase-3. There is crosstalk between mTOR and Bax, which acts as a gateway for caspase-mediated apopto-
sis. Compared with the control group, the protein level of Bax was significantly reduced in the Rap (1 μM) treated 
group as measured by western blot and fluorescence staining (both p < 0.05; see Supplementary Fig. S2A and 
S2B), suggesting that inhibition of mTOR decreased apoptosis markers.
Our results thus far suggest that luteolin could be a potential mTOR inhibitor, so next we examined if lute-
olin may affect the apoptosis related proteins, Bax, Cyt C and caspase-3. As shown in Fig. 4A and B, the protein 
levels of Bax and Cyt C significantly increased in the MG-treated group compared with the control group (all 
p < 0.05). Pretreatment with luteolin (1, 5 and 10 μM) for 3 h dose-dependently decreased the protein levels of 
Bax and Cyt C compared with the MG-treated group as examined by western blot (Fig. 4A and B). To further 
confirm the results, we determined the level of Bax, Cyt C and caspase-3 by immunofluorescent staining. As 
shown in Fig. 4C,D and E, the fluorescence intensity of Bax, Cyt C and caspase-3 were significantly increased in 
the MG-treated group compared with the control group (all p < 0.05). Pretreatment with 10 μM luteolin for 3 h 
significantly decreased the fluorescence intensity of Bax, Cyt C and caspase-3 compared with the MG group (all 
p < 0.05).
Discussion
Diabetic encephalopathy is now an accepted complication of diabetes and has become the focus of research in 
this field42, 43. High levels of MG have been found in the plasma of diabetic individuals44. The neurotoxicity of 
MG plays a causal role in the development of diabetic encephalopathy7. Our results confirm that MG inhibited 
cell viability in a dose-dependent manner and induced apoptosis of PC12 neuronal cells as measured by MTT, 
Hoechst 33258 dye staining and Annexin V-FITC/PI dual staining. These results were consistent with previous 
findings45, collectively highlighting that apoptosis is a major manner by which MG induces neuronal progenitor 
death. Our study extended this further to show that MG-induced apoptosis occurred via activation of mTOR 
signaling and the pro-apoptosis related Bax protein. More interestingly, we also found that the natural flavonoid, 
luteolin, could protect against MG induced apoptosis.
We have previously shown that luteolin protected against high fat diet-induced cognitive deficits in obese 
pre-diabetic mice46 and in STZ-induced diabetic rats38. In the present study, we demonstrated that luteolin pre-
vented MG-induced neuronal apoptosis, evidenced by the 37–60% increase in cell viability (measured by MTT) 
after pretreatment with luteolin (1–10 μM). Furthermore, the rate of MG-induced apoptotic PC12 cells was 
reduced after luteolin pretreatment, as detected by Hoechst 33258 dye staining. These findings suggest that luteo-
lin affords protection against MG-induced neuronal apoptosis. Combined with our previous animal studies38, 46, 
the present cell study suggests that the ability of luteolin to prevent apoptosis may contribute to its ability to 
improve cognitive deficits in diabetes.
The mitochondrial apoptosis pathway, Bcl-2/Bax/Cyt C/caspase-3, plays a major role in neuronal apoptosis 
in diabetes47–49. In the present study, luteolin prevented MG-induced activation of the pro-apoptotic Bax protein 
in PC12 cells, whilst also suppressing Cyt C and caspase-3 levels. Therefore, luteolin-induced reductions of the 
mitochondrial apoptosis pathway may inhibit neuronal apoptosis, contributing to an improvement of cognition 
in diabetes patients with elevated levels of MG.
Experimental evidence suggests that several pathways mediate AKT/mTOR-induced apoptosis, and one 
of these involves the Bax protein27. Bax, a pro-apoptotic member of the Bcl-2 family of proteins, is a target of 
mTOR50, 51. In cancer cells it has been shown that mTOR activates its downstream effector 4E-BP1 and p70S6K, 
which subsequently leads to translation of pro-apoptotic proteins27, 52 as well as phosphorylates and inactivation 
of the anti-apoptotic protein Bcl-228. Consistent with these findings, our study confirmed that the mTOR/4E-BP1 
signaling pathway modulates apoptosis and regulates the expression of the pro-apoptotic protein Bax in the 
PC12 cell. We report that Rap, as a blocker of mTOR/4E-BP1 signaling, significantly increased cell viability and 
decreased TUNEL-positive cell numbers, suggesting that inhibition of the mTOR/4E-BP1 signaling pathway 
protected PC12 cells from MG-induced neuronal apoptosis. In addition, immunofluorescent staining and west-
ern blotting analysis indicated that Rap pretreatment significantly inhibited the expression of the pro-apoptotic 
protein Bax. Previously, it was found that phosphorylated mTOR was significantly increased in the hippocam-
pus of STZ-induced diabetic mice, while inhibiting mTOR signaling by Rap prevented the cognitive deficits in 
this model29. Therefore, these findings including ours indicate that blocking mTOR/4E-BP1 down-regulates the 
expression of the pro-apoptotic protein Bax which may be important for reducing neuronal apoptosis during 
high MG status.
Interestingly, we found that luteolin pretreatment significantly inhibited the MG-induced activation of the 
mTOR/4E-BP1 signaling pathway in PC12 neuronal cells. This suggests that luteolin may act as an mTOR inhibi-
tor to reduce neuronal apoptosis. mTOR plays a key role in diabetes and its related Alzheimer’s pathogenesis29, 53, 
with an upregulation of mTOR reported in the brains of STZ-induced diabetic rodents29, 54 as well as in AD 
patients55. Altered mTOR signaling in AD was subsequently found to be associated with cognitive decline56. 
Modulating mTOR activity therefore provides an attractive avenue to discover new therapies to attenuate 
diabetic-related cognitive decline and prevent diabetic encephalopathy and AD. Here, we found that luteolin 
is a potent inhibitor similar as rapamycin to block mTOR/4E-BP1 as well as the expression of AKT and p70S6K 
and down-regulate the expression of pro-apoptotic protein Bax, Cyt C and casepase-3, indicating that it could 
be developed into an effective treatment for cognitive decline (Fig. 5). While this has not been trialed in diabetes 
or AD patients, two pilot, open-label, clinical studies using a luteolin-containing dietary formulation reported 
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Figure 4. Luteolin (Lut) inhibited MG-induced overexpression of Bax, Cyt C and caspase-3. The cells were 
pretreated with Lut (1, 5, 10 μM) for 3 h, followed by 0.5 mM MG administration for an additional 36 h. Bax 
(A) and Cyt C (B) were determined by western blotting analysis and the band densities were normalized with 
β-actin. Data are presented as means ± SD of three independent experiments, each performed in triplicate. 
#p < 0.01 vs control group; *p < 0.05 and **p < 0.01 vs MG group. The expression of Bax (C), Cyt C (D) and 
caspase-3 (E) was analyzed by immunofluorescent staining. Histograms show the quantification of the 
fluorescence intensity of the corresponding proteins. #p < 0.01 vs control group; *p < 0.05 vs MG group. The full-
length blots/gels are presented in Supplementary Figs S6 and S7.
www.nature.com/scientificreports/
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significant improvement in attention and sociability in children with Autism57, 58, supporting the potential transi-
tion of luteolin to the clinic for the treatment of diabetic encephalopathy and AD.
In summary, the findings presented in this study increase our understanding of the mechanistic pathway by 
which mTOR-induced neuronal apoptosis may play an important causal role in the MG-induced pathogenesis of 
diabetic encephalopathy. Targeting mTOR may provide important novel therapeutic approaches for MG-induced 
diabetic encephalopathy. Luteolin, a herb derived natural flavonoid, improved MG-induced cell apoptosis and 
decreased the expression of the pro-apoptotic Bax protein as well as Cyt C and casepase-3. Furthermore, luteolin 
acts as an mTOR inhibitor contributing to protection against MG-induced neuronal apoptosis. In addition, fla-
vonoid luteolin could target multiple signaling kinases, and not necessarily only the mTOR and apoptotic path-
ways, for its neuroprotective effects. Further research into the effects of luteolin on signaling pathways involved 
in neuroinflamamtion and oxidative stress should be investigated as flavonoids are considered to be capable of 
counteracting neuroinflammation and oxidative stress.
Materials and Methods
Materials. 3-(4,5-Dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and MG (40%, w/v), 
Propidium Iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Luteolin (purity > 98%) was 
purchased from Shanxi Sciphar Biotechnology Co., Ltd (Shanxi, China). Fetal bovine serum (FBS) and Dulbecco’s 
modified Eagle medium (DMEM) were obtained from Gibco (Grand Island, NY, USA). mTOR, phospho-mTOR 
(Ser2448), phospho-4E-BP1 (Thr37/46), AKT, phospho-AKT (Ser473), phospho-p70S6K (Thr389) were pur-
chased from Cell Signaling Technology (Danvers, MA, USA). Anti-Cytochrome C antibody was purchased from 
Abcam (Cambridge, UK). Antibodies against Bax and Bcl-2 were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Mouse anti-β-actin monoclonal antibody was purchased from Abmart (Shanghai, China). All 
secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture and treatment. PC12 cells were obtained from the Chinese Type Culture Collection 
(Shanghai, China). The cells were grown in DMEM containing 10% FBS, 100 U/mL penicillin and 100 U/mL 
streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. For experiments indicated below, PC12 
cells were exposed to MG at various concentrations (0.1–2 mM) for different time periods (12, 24, 36 h). Luteolin 
(1, 5, 10 μM) was added 3 h prior to MG administration. Rapamycin (Rap) (1 μM) was added 1 h prior to MG 
administration.
Cell viability assay. PC12 cells were seeded in 96-well plates at a density of 5 × 103 cells/well. The cells were 
grown for 12 h, and the medium was changed to that containing various concentrations (0.1, 0.25, 0.5, 1 and 
2 mM) of MG. All measurements were performed at 36 h after the cells were exposed to MG. Cytotoxicity of MG 
was measured by MTT assay.
PC12 cells were pretreated with different concentrations (1, 5, 10 μM) of Luteolin, after which they were cul-
tured with 0.5 mM MG for 36 h. MTT (0.5 mg/mL) was then added to each well and the cells were cultured for 
an additional 4 h. Finally, the MTT was carefully removed by aspiration, the formazan crystals were dissolved in 
dimethyl sulfoxide and the absorbance was read at 550 nm using a microplate reader.
Figure 5. A proposed model of molecular targets of Luteolin (Lut) in preventing MG-induced apoptosis. Our 
study found that Lut prevents MG-induced apoptosis by decreasing protein phosphorylation of mTOR, and 
4E-BP1 in PC12 cells. Furthermore, our study also confirmed the mTOR/4E-BP1 signaling pathway modulates 
apoptosis and regulates the expression of the pro-apoptotic protein Bax in PC12 cells. This suggests that Lut 
prevented MG-induced cell apoptosis and decreased the expression of the pro-apoptotic Bax protein and Cyt C 
and casepase-3 through inhibiting mTOR/4E-BP1 signaling pathway.
www.nature.com/scientificreports/
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Observation of morphologic changes. PC12 cells were seeded in 6-well plates at a density of 7 × 104 
cells/well. The cells were grown for 12 h, and the medium was changed to that containing various concentrations 
(0.1, 0.25, 0.5, 1 and 2 mM) of MG. After the cells were exposed to MG for 36 h, the cellular morphology was 
observed under a phase-contrast microscope at 100x magnification with a CCD camera (OLYMPUS IX73, Japan).
Nuclear staining with Hoechst 33258. To assess changes in nuclear morphology during apoptosis, cells 
were stained with the fluorescent nuclear dye Hoechst 33258. Briefly, PC12 cells were seeded into 6-well plates at 
a density of 7 × 104 cells/well and incubated at 37 °C for 12 h with various concentrations of different experimental 
compounds. After treatment, cells were fixed with paraformaldehyde (4.0%), washed twice with ice-cold PBS and 
stained with Hoechst 33258 staining solution for 10 min at room temperature. Using inverted fluorescent micros-
copy, fragmented or condensed nuclei were scored as apoptotic based on their morphology.
TUNEL assay. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is a method for 
detecting DNA fragmentation by labeling the terminal end of nucleic acids. Apoptosis was evaluated with the 
TUNEL BrightRed Apoptosis Detection kit (Vazyme Biotech Co., Ltd. Nanjing, China) according to the manufac-
turer’s instructions. Briefly, 5 × 104 cells/ml were plated in 6-well flat-bottom plates and pretreated with 1 μM Rap 
for 1 h and then treated with 0.5 mM MG for 36 h. Cells were fixed in 4% paraformaldehyde at 4 °C for 30 min, and 
then permeabilized in 0.1% Triton X-100. Cells were then washed and stained with TUNEL reaction mixture and 
DAPI (Sigma, St. Louis, MO). The image was visualized and captured by microscope (Olympus × 51 W, Olympus 
Microsystems).
Flow cytometry analysis for apoptosis. The apoptotic cells were quantitated using annexin V-FITC/
Propidium Iodide (PI) apoptosis assay kits. Briefly, PC12 cells were seeded into 6-well plates at a density of 1 × 105 
cells/well and incubated with various concentrations of different experimental compounds at 37 °C for 12 h. After 
treatment, PC12 cells were washed twice with PBS and detached by pipette. The cells were then centrifuged 
at 1000 rpm for 5 min and washed with PBS twice. Cells were stained with Annexin V-FITC and PI by using 
Annexin V-FITC kit (Jiangsu KeyGEN BioTECH Co., Ltd. Jiangsu, China) and collected for flow cytometry 
analysis with emission filters of 525 and 575 nm, respectively. Approximately 1 × 104 counts were made for each 
sample. The percentages of early apoptotic (Annexin V-FITC+/PI−) and late apoptotic (Annexin V-FITC+/PI+) 
cells were calculated by CELL Quest software.
Immunofluorescent staining. PC12 cells were seeded on glass cover slips in a 24-well plate at 1 × 104 
cells/well and cultured with various concentrations of different experimental compounds at 37 °C for 12 h. After 
treatment, PC12 cells were washed three times with ice-cold PBS, immediately fixed in 4% paraformaldehyde for 
30 min and permeabilized with 0.5% Triton X-100 for 15 min. The cells were incubated with primary antibodies 
against Bax, caspase-3, p-mTOR and p-4E-BP1 (1:50 dilution) overnight at 4 °C. Cells were then washed three 
times with PBS, incubated with FITC-conjugated goat anti-rabbit secondary antibody (1:200 dilution) for 2 h at 
room temperature. Cells were washed three times in PBS, and stained with DAPI or PI (10 μg/mL) for nuclear 
identification. The image was visualized and captured by microscope (Olympus x51 W, Olympus Microsystems).
Western blot analysis. After treatment as described above, PC12 cells were washed twice with ice-cold PBS 
(pH 7.4) and centrifuged at 1000 rpm for 5 min. Cell pellets were lysed in an ice cold extraction buffer (20 mM 
Tris-HCl buffer, pH 7.6, 150 mM NaCl, 2 mM EDTA·2Na, 50 mM sodium fluoride, 1 mM sodium vanadate, 1% 
NonidetTM P-40, 1% sodium deoxycholate, 0.1% SDS, 1 mg/ml aprotinin, and 1 mg/ml leupeptin). Cell lysates 
were centrifuged at 12000 g for 15 min at 4 °C. The supernatant was collected and used for further analysis.
The protein concentration was determined by the BCA Protein Assay Kit (Sigma–Aldrich) using bovine 
serum albumin (BSA) as the standard. Equal amounts of protein (50 μg protein/lane) were electrophoresed on 
8–12% density SDS-acrylamide gels. Following electrophoresis, the proteins were transferred to a nitrocellulose 
filter (NC) membrane using an electric transfer system. The membrane was blocked with 5% (v/v) skim milk 
powder in Tris-buffered saline with Tween 20 (TBST; 10 mM Tris-HCl, 150 mM NaCl and 0.1% Tween 20, pH 7.5) 
at room temperature for 1 h. The membranes were incubated with primary antibodies against Bcl-2 (1:600), Bax 
(1:500), Cytochrome C (1:600), mTOR (1:600), phospho-mTOR (1:500), AKT (1:100), phospho-AKT (1:1000), 
phospho-4E-BP1(1:1000), phospho-p70S6K (1:1000) and β-actin (1:500) overnight at 4 °C. The membranes were 
washed three times with 1 × TBST for 5 min each. The membranes were incubated with the appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibody at room temperature for another 2 h and washed again 
three times in TBST buffer.
Statistical analysis. Data were expressed as mean ± SD of at least three independent experiments. Data 
were analyzed by one-way ANOVA followed by Dunnett’s post hoc test. p < 0.05 was considered to be statistically 
significant. Statistical analysis was conducted using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
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